Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526005 · ClinicalTrials.gov registry record
Brain Nicotine Receptor Density & Response to Nicotine Patch
A clinical trial of Cigarette Smoking, sponsored by Brentwood Biomedical Research Institute.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT01526005 is a study of Cigarette Smoking that has completed, run by Brentwood Biomedical Research Institute. The registered enrollment target is 50 participants, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01526005, a study of Cigarette Smoking, has completed, sponsored by Brentwood Biomedical Research Institute.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Even though the health risks and societal costs of cigarette smoking are well-known, roughly 19.8% of American adults continue to smoke. While most smokers endorse a desire to quit, very few (\< 5%) will actually quit in a given year without treatment, and only about 20-25% achieve abstinence after 6 months or more of effective treatment. Therefore, there continues to be a vital need to improve outcomes for cigarette smokers seeking treatment. Current first-line medications for Tobacco Dependence include nicotine replacement therapies (such as the patch, gum, lozenge, nasal spray, and inhaler), varenicline HCl (Chantix), and bupropion HCl (Zyban), with the current standard of care in most treatment settings being to choose specific medications based primarily on availability, ease of use, and patient preference. The goal of the proposed research is to improve the delivery of smoking cessation treatment by determining if pre-treatment nicotine receptor density in cigarette smokers is associated with smoking cessation outcome with the standard nicotine patch taper. The study's main hypothesis is that cigarette smokers with less pre-treatment upregulation of nicotine receptors will have a greater likelihood of quitting smoking from a standard course of nicotine patch treatment than smokers with more up-regulation of these receptors. Positron emission tomography (PET) will be used to test this hypothesis.
Conditions Studied
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG Transdermal Placebo Patch
Study Locations (1)
California
- West Los Angeles Veterans Affairs Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526005
The ClinicalTrials.gov registry entry for NCT01526005 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (71% lower). The listed sponsor is Brentwood Biomedical Research Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cigarette Smoking appearing as the primary indexed condition, and to 2 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT01526005 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01526005 about?
NCT01526005 is a clinical study titled "Brain Nicotine Receptor Density & Response to Nicotine Patch". Even though the health risks and societal costs of cigarette smoking are well-known, roughly 19.8% of American adults continue to smoke. While most smokers endorse a desire to quit, very few (\< 5%) will actually quit in a given year without treatment, and only about 20-25% achieve abstinence after ...
What is the current status of trial NCT01526005?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2012-03.
What conditions does trial NCT01526005 study?
This clinical trial studies the following conditions: Cigarette Smoking.
What interventions are being tested in trial NCT01526005?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), Transdermal Placebo Patch (DRUG).
Who is sponsoring clinical trial NCT01526005?
This trial is sponsored by Brentwood Biomedical Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01526005 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing
RECRUITING · NA
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
-
Menthol, Inflammation, and Nicotine Transition Study
RECRUITING · NA
-
RTMS Targets Neural Circuits for Smoking Cessation
RECRUITING · NA
-
Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.